$151 Million is the total value of Opus Point Partners Management, LLC's 57 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XNPT | Exit | XENOPORT INC | $0 | – | -40,000 | -100.0% | -0.08% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -15,000 | -100.0% | -0.08% | – |
| ACRX | Exit | ACELRX PHARMACEUTICALS INC | $0 | – | -57,747 | -100.0% | -0.10% | – |
| LABU | Exit | DIREXION SHS ETF TR | $0 | – | -14,850 | -100.0% | -0.13% | – |
| NHLD | Exit | NATIONAL HOLDINGS CORP | $0 | – | -89,530 | -100.0% | -0.14% | – |
| ARWR | Exit | ARROWHEAD RESH CORP | $0 | – | -51,133 | -100.0% | -0.16% | – |
| RPRX | Exit | REPROS THERAPEUTICS INCcall | $0 | – | -98,000 | -100.0% | -0.27% | – |
| CMRX | Exit | CHIMERIX INC | $0 | – | -14,152 | -100.0% | -0.30% | – |
| STML | Exit | STEMLINE THERAPEUTICS INC | $0 | – | -75,000 | -100.0% | -0.37% | – |
| CRIS | Exit | CURIS INC | $0 | – | -374,500 | -100.0% | -0.42% | – |
| ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -250,000 | -100.0% | -0.63% | – |
| CPHD | Exit | CEPHEID | $0 | – | -90,000 | -100.0% | -2.25% | – |
| ISIS | Exit | ISIS PHARMACEUTICALS INC | $0 | – | -101,401 | -100.0% | -2.26% | – |
| TECH | Exit | BIO TECHNE CORP | $0 | – | -47,000 | -100.0% | -2.40% | – |
| XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -862,500 | -100.0% | -29.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.